Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas Blood, Mar 2013; 121: 2563 - 2566.
[anti-HA]
Regulation of the PI3-K/Akt Survival Pathway in the Rat Endometrium Biol Reprod, Mar 2013; 88: 79.
[Akt3]
RNA elements directing in vivo assembly of the 7SK/MePCE/Larp7 transcriptional regulatory snRNP Nucleic Acids Res., Mar 2013; 10.1093/nar/gkt159.
[LA]
Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements Haematologica, Mar 2013; 98: 404 - 408.
[JAK2]
Homo sapiens eukaryotic translation initiation factor 4E binding protein 1 (EIF4EBP1)
Synonyms:
4E-BP1; 4EBP1; BP-1; PHAS-I
Immunogen
A phospho-specific peptide corresponding to residues surrounding serine 65 of human 4E-BP1 was used as an immunogen. This antibody detects 4E-BP1 phosphorylated at serine 65.
Buffer
50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.
4E-BP1 (eIF4E-binding protein) also known as PHAS, is a 10-12 kDa acidic protein that compete with eIF4G for binding of eiF4E to the mRNA 5 cap structure (1). Binding of the 4E-BPs to eIF4E is reversible and is dependent on the phosphorylation status of 4E-BP. Non-phosphorylated 4E-BP1 will bind strongly to eiF4E while, the phosphorylated form will no (2)t. Akt, TOR, MAP kinase, S6 kinase, and Cdc2 are known kinases capable of inactivating 4E-BP1 binding to eIF4E by phosphorylating either threonines 35, 45, 69 or serine 65. Although, not all phosphorylation events equally block the 4EBP1-eIF4E interaction (3-4)
Related Pathway
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
Western blot analysis on NIH-3T3 cell lysates using anti- Phospho-4E-BP1 (pS65), 1:2000 dilution. Cells were either (A) untreated (B) treated with PDGF.
Researchers who bought this antibody have also purchased:
